872P - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
The treatment of metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
TAUBER R;
FEUERECKER Benedikt;
KNORR Karina;
BEHESHTI A;
SEIDL C.;
D'ALESSANDRIA C;
BRUCHERTSEIFER Frank;
RETZ M;
GSCHWEND J.E.;
WEBER Wolfgang;
MORGENSTERN Alfred;
EIBER Matthias;
2020-03-02
OXFORD UNIV PRESS
JRC116691
0923-7534 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116691,
10.1093/annonc/mdz248.029 (online),
Additional supporting files
| File name | Description | File type | |
|---|
